ES2494840T3 - Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas - Google Patents

Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas Download PDF

Info

Publication number
ES2494840T3
ES2494840T3 ES06723429.4T ES06723429T ES2494840T3 ES 2494840 T3 ES2494840 T3 ES 2494840T3 ES 06723429 T ES06723429 T ES 06723429T ES 2494840 T3 ES2494840 T3 ES 2494840T3
Authority
ES
Spain
Prior art keywords
seq
hbv
hepatitis
polynucleic acid
nucleoside analogues
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES06723429.4T
Other languages
English (en)
Inventor
Mithat Bozdayi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujirebio Europe NV SA
Original Assignee
Fujirebio Europe NV SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujirebio Europe NV SA filed Critical Fujirebio Europe NV SA
Application granted granted Critical
Publication of ES2494840T3 publication Critical patent/ES2494840T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
    • C12Q1/701—Specific hybridization probes
    • C12Q1/706—Specific hybridization probes for hepatitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Un ácido polinucleico de VHB aislado que codifica una variante de VHB, dicho ácido polinucleico de VHB comprende una mutación nucleotídica que produce sustitución de aminoácidos rtA181S del gen de la ADN polimerasa en la variante de VHB, en donde dicha mutación nucleotídica produce una sensibilidad disminuida al análogo de nucleósido adefovir y lamivudina, dicho ácido polinucleico de VHB comprende un ácido polinucleico elegido del grupo que consiste en SEQ ID 2, SEQ ID 3, SEQ ID 5, SEQ ID 6 y SEQ ID 7.

Description

imagen1
imagen2
imagen3
imagen4
imagen5
imagen6
imagen7
imagen8
imagen9
imagen10
imagen11
imagen12
imagen13
imagen14
imagen15
imagen16
imagen17
imagen18
imagen19
imagen20
imagen21
imagen22
imagen23

Claims (1)

  1. imagen1
    imagen2
ES06723429.4T 2005-03-15 2006-03-14 Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas Expired - Lifetime ES2494840T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66148405P 2005-03-15 2005-03-15
US661484P 2005-03-15
EP05101997 2005-03-15
EP05101997 2005-03-15
PCT/EP2006/002352 WO2006097285A1 (en) 2005-03-15 2006-03-14 Hepatitis-b viral variants with reduced susceptibility to nucleoside analogs and uses thereof

Publications (1)

Publication Number Publication Date
ES2494840T3 true ES2494840T3 (es) 2014-09-16

Family

ID=35355552

Family Applications (1)

Application Number Title Priority Date Filing Date
ES06723429.4T Expired - Lifetime ES2494840T3 (es) 2005-03-15 2006-03-14 Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas

Country Status (10)

Country Link
US (1) US7422848B2 (es)
EP (1) EP1858916B1 (es)
JP (1) JP2008537483A (es)
CN (1) CN101203528A (es)
AU (1) AU2006224789B2 (es)
ES (1) ES2494840T3 (es)
NZ (1) NZ562467A (es)
PL (1) PL1858916T4 (es)
PT (1) PT1858916E (es)
WO (1) WO2006097285A1 (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPO351996A0 (en) * 1996-11-08 1996-12-05 Western Health Care Network Viral variants and methods for detecting same
USRE40233E1 (en) 1996-11-08 2008-04-08 Melbourne Health Viral variants and methods for detecting same
US7405039B2 (en) 2002-02-07 2008-07-29 Austin Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
US8278432B2 (en) 2002-03-29 2012-10-02 Innogenetics N.V. HBV drug resistance methods
WO2003087351A1 (en) 2002-04-12 2003-10-23 Melbourne Health Hepatitis b viral variants with redused susceptibility to nucleoside analogs and uses thereof
WO2006097284A1 (en) * 2005-03-15 2006-09-21 Rheinische Friedrich-Wilhelms-Universität Bonn Variants of hepatitis b virus resistant against some nucleoside analogues, but sensitive to others, and uses thereof
ES2494840T3 (es) 2005-03-15 2014-09-16 Fujirebio Europe N.V. Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas
AU2006230802A1 (en) * 2005-04-08 2006-10-12 Austin Health Variants of hepatitis B virus with resistance to anti-viral nucleoside agents and applications thereof
JP2008534020A (ja) 2005-04-08 2008-08-28 メルボルン ヘルス 抗ウイルス性のヌクレオシド剤に耐性を示すｂ型肝炎ウイルスのバリアントおよびその応用法
KR101110013B1 (ko) * 2007-10-05 2012-02-29 (주)바이오니아 서열 내에 어베이직 부분을 포함하는 ｐｃｒ 증폭용프라이머
JP2009213465A (ja) * 2007-10-30 2009-09-24 Toshiba Corp Ｂ型肝炎ウイルス薬剤耐性株検出用核酸プライマーセット、アッセイキットおよびｂ型肝炎ウィルスの薬剤耐性株の検出方法
CA2950863C (en) 2014-06-02 2023-01-17 Isa Pharmaceuticals B.V. Synthetic long peptides (slp) for therapeutic vaccination against hepatitis b virus infection
US9963751B2 (en) 2015-11-24 2018-05-08 The Penn State Research Foundation Compositions and methods for identifying agents to reduce hepatitis B virus covalently closed circular DNA
SG11202105276TA (en) 2018-12-03 2021-06-29 Univ Texas Oligo-benzamide analogs and their use in cancer treatment

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576175A (en) 1989-09-20 1996-11-19 Immuno Aktiengesellschaft Complex suitable for carrying out a method of purifying pre-S hepatitis B surface antigen
US5858328A (en) 1991-06-04 1999-01-12 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
US5849987A (en) 1992-06-02 1998-12-15 Yeda Research And Development Co. Ltd. Animal model for hepatitis virus infection
WO1994001554A1 (en) 1992-07-08 1994-01-20 N.V. Innogenetics S.A. Polypeptides, derived from endonexin 2, having hepatitis b virus receptor activity and their use in diagnostic and pharmaceutical compositions
US5595739A (en) 1993-05-07 1997-01-21 Abbott Laboratories Hepatitis B virus mutants, reagents and methods for detection
US6100068A (en) 1997-01-21 2000-08-08 Paik-Inje Memorial Institute For Biomedical Science Method of protein production using mitochondrial translation system
US6242187B1 (en) 1996-01-29 2001-06-05 Virologic, Inc. Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening
US5817457A (en) 1996-02-07 1998-10-06 Ma Bioservices, Inc. Methods and kits for detecting viral reverse transcriptase activity in a sample using an acidic pH or an elevated temperature
US5877162A (en) 1996-03-14 1999-03-02 Innovir Laboratories, Inc. Short external guide sequences
ZA973367B (en) 1996-04-19 1997-11-18 Innogenetics Nv Method for typing and detecting HBV.
ES2183166T3 (es) 1996-04-26 2003-03-16 Massachusetts Inst Technology Ensayo de cribado por triple hibrido.
CN1231695A (zh) 1996-08-16 1999-10-13 同和药品工业株式会社 HBV聚合酶,起源于HBV聚合酶的RNaseH,其制备过程和在筛选抗病毒剂中的应用
AUPO351996A0 (en) 1996-11-08 1996-12-05 Western Health Care Network Viral variants and methods for detecting same
US5939541A (en) 1997-03-28 1999-08-17 University Of South Carolina Method for enhancing expression of a foreign or endogenous gene product in plants
AU762355B2 (en) 1998-01-21 2003-06-26 Penn State Research Foundation, The Methods and compositions to investigate infection by hepatitis B virus and agents to prevent and treat the infection
US6150105A (en) 1998-08-20 2000-11-21 Genetic Assays, Inc. Methods of screening nucleic acids for nucleotide variations
JP2000270876A (ja) 1999-03-26 2000-10-03 Genome Science Laboratories Co Ltd Ｂ型肝炎ウイルス遺伝子の変異検出方法および検出キット
AUPP967999A0 (en) 1999-04-09 1999-05-06 North Western Health Care Network Viral variants
CA2370872C (en) 1999-04-30 2007-02-06 Sequenom, Inc. Diagnostic sequencing by a combination of specific cleavage and mass spectrometry
EP2319917A3 (en) * 2002-02-07 2012-02-08 Melbourne Health Viral variants with altered susceptibility to nucleoside analogs and uses thereof
US8278432B2 (en) 2002-03-29 2012-10-02 Innogenetics N.V. HBV drug resistance methods
WO2003087351A1 (en) * 2002-04-12 2003-10-23 Melbourne Health Hepatitis b viral variants with redused susceptibility to nucleoside analogs and uses thereof
WO2004031224A2 (en) 2002-10-01 2004-04-15 Gilead Sciences, Inc. Hbv mutations associated with reduced susceptibility to adefovir
WO2006097284A1 (en) 2005-03-15 2006-09-21 Rheinische Friedrich-Wilhelms-Universität Bonn Variants of hepatitis b virus resistant against some nucleoside analogues, but sensitive to others, and uses thereof
ES2494840T3 (es) 2005-03-15 2014-09-16 Fujirebio Europe N.V. Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas

Also Published As

Publication number Publication date
WO2006097285A1 (en) 2006-09-21
PT1858916E (pt) 2014-10-06
PL1858916T3 (pl) 2015-01-30
PL1858916T4 (pl) 2015-04-30
JP2008537483A (ja) 2008-09-18
CN101203528A (zh) 2008-06-18
US7422848B2 (en) 2008-09-09
AU2006224789B2 (en) 2012-09-06
US20060234212A1 (en) 2006-10-19
EP1858916A1 (en) 2007-11-28
AU2006224789A1 (en) 2006-09-21
EP1858916B1 (en) 2014-07-09
NZ562467A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
ES2494840T3 (es) Variantes víricas de la hepatitis B con susceptibilidad reducida a análogos de nucleósidos y usos de las mismas
JP7538807B2 (ja) テンプレートなしの酵素によるポリヌクレオチド合成における効率的生成物切断
Williams et al. Regulation of viral infection by the RNA modification N6-methyladenosine
US20200139335A1 (en) Enrichment of DNA Sequencing Libraries from Samples Containing Small Amounts of Target DNA
CY1120186T1 (el) Τροποποιημενα νουκλεοτιδια για αλληλουχιση πολυνουκλεοτιδιωn
ES2304739T3 (es) Metodos de genotipaje utilizando diferencias en la temperatura de fusion.
ATE557084T1 (de) Modifizierte dna-polymerasen zur verbesserten inkorporation von nukleotidanaloga
RU2011137526A (ru) Способ амплификации gс-богатых матриц днк
WO2007016668A3 (en) Methods and compositions for disease prognosis based on nucleic acid methylation
Cuevas et al. Human norovirus hyper-mutation revealed by ultra-deep sequencing
Tedder et al. The ‘Red Queen’dilemma–running to stay in the same place: refections on the evolutionary vector of HBV in humans
US12516302B2 (en) DNA polymerase theta mutants, methods of producing these mutants, and their uses
JP2022543568A (ja) ポリヌクレオチドの鋳型なしの酵素による合成における長い配列の収量の増加
Haasnoot et al. The Brome mosaic virus subgenomic promoter hairpin is structurally similar to the iron-responsive element and functionally equivalent to the minus-strand core promoter stem-loop C.
Furano et al. Cryptic genetic variation enhances primate L1 retrotransposon survival by enlarging the functional coiled coil sequence space of ORF1p
WO2007076493A8 (en) Methods and reagents for genotyping hcv
JP2019140953A5 (es)
EP1904518A4 (en) DNA POLYMERASE MIXTURES AND MUTANT DNA POLYMERASES
WO2008136470A1 (ja) Ｈｃｖ遺伝子
Tarashima et al. Synthesis of DNA fragments containing 2′-deoxy-4′-selenonucleoside units using DNA polymerases: Comparison of dNTPs with O, S and Se at the 4′-position in replication
Umeda et al. Both heavy strand replication origins are active in partially duplicated human mitochondrial DNAs
Faure Alternative peptide-fusion proteins generated by out-of-frame mutations, just upstream ORFs or elongations in mutants of human hepatitis B viruses
WO2003093461A8 (fr) Banque genomique du cyanophage s-2l et analyse fonctionnelle
RU2009104533A (ru) Способы обнаружения болезни альцгеймера
JP2007215481A5 (es)